Pembrolizumab with platinum and 5‐fluorouracil is an effective first‐line therapy for chronic or metastatic HNSCC, and pembrolizumab alone is an acceptable first‐line therapy for PD‐L1‐positive chronic or metastatic HNSCCC, based on the effectiveness and safety detected. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.